| Program : Melogliptin (GRC 8200) |
Phase IIB Complete |
|
|
| Target / Indication |
A (DPP) IV Inhibitor indicated for Diabetes (Type II) |
| Highlights |
| |
|
Potential Best-in-Class in terms of safety and efficacy |
| |
|
The molecule is expected to enter Phase III before the end of the financial year (FY 2010) |
| |
|
DPP IV is one of the most promising treatment pathway to come up in the large and growing diabetes market |
| |
|
Currently being developed as monotherapy as well as combination therapy with other anti-diabetic molecules |
|
| Market Opportunity |
| |
|
125 mn patients worldwide / Market Size: USD 35 bn by 2015 |
|
| Potential Peak Sales |
USD 1 bn worldwide |
|